Skip to Main Content

Meet Dr. Kelly Olino

September 21, 2021

Dr. Olino is a surgical oncologist that specializes in the care of patients with advanced skin cancers and sarcomas and she discusses how she collaborates with other disciplines to provide patients with a cohesive experience.

ID
6913

Transcript

  • 00:00Hi, my name is Kelly Olino.
  • 00:03I'm a surgical oncologist,
  • 00:04and at the Yale Cancer Center I treat
  • 00:07patients with advanced skin cancers including
  • 00:09Melanoma and Merkel cell carcinomas,
  • 00:11and in addition to that I'm also an
  • 00:14expert in the treatment of sarcoma.
  • 00:16We're very fortunate that we really
  • 00:18have a wonderful team approach from
  • 00:21the minute patient picks up the phone,
  • 00:23the person that they speak to on the
  • 00:26other end really enables for us to have
  • 00:29a seamless transition from their first.
  • 00:31Appointment to the clinic visit.
  • 00:34We have a multidisciplinary group of people
  • 00:36and that includes surgeons like myself,
  • 00:39plastic surgery,
  • 00:40dermatology as well as medical
  • 00:43oncology which really allows for
  • 00:45both our skin cancer patients and
  • 00:47our sarcoma patients to really have
  • 00:50one stop access to all of their
  • 00:52providers and for it to really be a
  • 00:55very cohesive and seamless experience.
  • 00:58Patients should always feel free
  • 01:00to bring lists of questions.
  • 01:02And concerns, because, again,
  • 01:04there's so much information via
  • 01:05in the Internet and social media.
  • 01:07I'd much rather people come in with
  • 01:10questions that they have and use me
  • 01:12as almost their own personal medical
  • 01:14encyclopedia and have every single
  • 01:16one of those questions answered by the
  • 01:18time that the clinic visit is over.
  • 01:21And again to know that if they
  • 01:23have additional questions,
  • 01:24it's always OK to call again one
  • 01:26of the main focus that we have,
  • 01:29particularly with Melanoma,
  • 01:30which was one of the early successes.
  • 01:32In the treatment of immune therapy is
  • 01:35to see how we can improve the platform,
  • 01:38both in how we can minimize side
  • 01:41effects while increasing the
  • 01:42number of people who respond.
  • 01:44For example,
  • 01:45work that we've done and successfully
  • 01:48taken from the laboratory now
  • 01:50to the clinic has focused on
  • 01:52a new target known as CD 40,
  • 01:54and that actually led to us enabling
  • 01:56to open a clinical trial which is
  • 01:59now under active investigation,
  • 02:01which really was the culmination.
  • 02:03Of this seamless teamwork that
  • 02:04I alluded to earlier,
  • 02:06where patients have the benefit of us
  • 02:08going from the bench to the bedside
  • 02:10and then back to the bench to try
  • 02:13and improve upon our treatments.